Bacterial Biofilm Infections: Personalizing Patient Treatment

Share Article

Research scientists and physicians aim to use real-time cell analysis instruments to quickly characterize, ex vivo, the antibiotic susceptibility of bacterial biofilm infections prior to treating patients

Bacterial biofilms, surface adherent communities of bacteria that are encased in a secreted extracellular matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum disease and the rejection of medical implants. Though the economic impact of biofilms is in the tens of billions of dollars per year, there is currently a paucity of means for preventing their formation or treating them once they are established. Compared to the free-floating “planktonic” lifestyle, within biofilms bacteria adopt differential gene expression profiles, have heightened resistance to antibiotics (up to 1,000-fold), and are less detectable/ accessible to the immune system. The current approach for treating biofilm infections is far from optimal: antibiotics are administered in a trial-and-error manner.

To reduce the time required for eliminating a biofilm infection, lower the cost of treatment, and improve the patient’s experience, it would be helpful to empirically identify the most efficacious antibiotic prior to initiating treatment. Towards this end, Dr. Alex Mira and colleagues at the Centre for Advanced Research in Public Health (Valencia, Spain) recently announced an initiative to personalize the treatment of biofilm infections using a novel ex vivo antibiotic screening assay. In their protocol, bacteria from biofilm growing on a patient’s catheter, medical implant, infected gums, etc. are isolated and grown in specialized electronic microtiter plates (E-Plates®) in the presence or absence of diverse antibiotics. An xCELLigence instrument, which uses the principle of cellular impedance to track the real-time growth of both the bacteria and their extracellular matrix inside E-Plates, is then used to rank order the efficacy of the different antibiotics tested. Using this approach, in just 8 hours a physician can identify the optimal therapeutic course of action on a patient by patient basis.

The primary objective of this initiative’s ongoing first phase is to determine how accurate the ex vivo xCELLigence assay is for predicting antibiotic efficacy in patients. With the backing of Minister of Health Carmen Montón, the project has been fast-tracked and Mira’s team is expecting to enroll 100 patients over the first year. If the clinical findings reflect the preliminary data, this personalized approach will revolutionize how biofilm infections are treated in the near future.

About xCELLigence® RTCA
xCELLigence® Real Time Cell Analysis (RTCA) instruments utilize gold microelectrodes embedded in the bottom of microtiter wells to non-invasively monitor the status of adherent cells using the principle of cellular impedance. In short, cells act as insulators – impeding the flow of a miniscule electric current between electrodes. This impedance signal is measured automatically, at an interval defined by the user, and provides an extremely sensitive readout of cell number, cell size, cell-substrate attachment strength, and cell invasion/migration. xCELLigence® RTCA instruments are being used in both academia and industry for basic and applied applications ranging from bacterial biofilms and cancer immunotherapy to cardiotoxicity and drug discovery. To date xCELLigence® has been used in more than 1,250 publications, which can be viewed in a searchable library.

About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. ACEA’s xCELLigence® impedance-based, label-free, real-time cell analysis instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,300 instruments have been placed globally.

For more information, click here.

For further information please contact:                                                                                    
ACEA Biosciences, Inc.                                                                                                                
Dr. Jeff Xue                                                                                                                                    
Phone: 1-858-724-0928, x3075                                                                                                
email: jxue(at)aceabio(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Xue, Ph.D.
ACEA Biosciences, Inc.
+1 8587240928 Ext: 3075
Email >
@aceabiosciences
Follow >
Follow us on
Visit website